Fox News senior medical analyst Dr. Marc Siegel joins 'America's Newsroom' to discuss the approval of a GLP-1 pill for weight ...

Novo Nordisk plans to quickly launch the pill form of Wegovy but is expected to soon face competition from Eli Lilly.

Randomised trial data show GLP 1 receptor agonists are associated with increased risk of gallbladder and biliary disease, ...

It’s like a switch that goes on and you’re instantly starving.” Tanya Hall’s words capture a reality many face when they stop ...

The new drug, simply called the Wegovy pill, marks a turning point in the modern weight-loss revolution. Until now, every ...

The Wegovy pill is one of two oral GLP-1 drugs expected to hit the market in the next few months; the other, from Lilly, is called orforglipron – until it receives a brand name – and is expected to be ...

After ushering in a new era of obesity treatment with its GLP-1 medicine Wegovy earlier in the decade, Novo Nordisk is making ...

The next transformative phase of weight-loss medication is upon us, with the US Food and Drug Administration (FDA) approving ...

Danish pharmaceutical manufacturer Novo Nordisk on Dec. 22 announced that the U.S. Food and Drug Administration (FDA) has ...

Until now, the most widely used GLP-1 medicines for weight loss have been injections. Novo Nordisk is pitching the newly approved Wegovy pill as a more convenient, once-daily option that could broaden ...

People who switched to the experimental daily GLP-1 pill orforglipron were able to maintain their weight loss after stopping ...

The FDA has approved the first oral glucagon-like peptide-1 (GLP-1) receptor agonist for weight loss and to reduce the risk ...